tool servic evolv better place
select
compani data secur llc estim
initi coverag life scienc tool servic
diagnost sector
pleas refer long form initi report titl tool servic
evolv better place select in-
depth review sever secular theme rate distribut trade-
off recap ground level work weve
industri chang better advoc
select approach see report detail
sector boast greater secular growth year ago
exposur biopharma china less cyclic
pharma servic benefit strong demand broaden
larg clinic lab enjoy best manag care access year
market recogn posit rel valuat
growth deceler end market trend mix
present slide well
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani cover
research report result investor awar firm may
conflict interest could affect object report
investor consid report singl factor make
downsid risk overweight rate includ limit global macro deterior
well deterior demand trend specif china given region rel import
growth furthermor slowdown demand compani pharma/biotech industri would
headwind growth final addit risk aris potenti lack slowdown new product
adopt demand disrupt outsourc nucleic acid activ pharmaceut ingredi
acquisit target select integr
downsid risk overweight rate includ limit follow factor first
slowdown demand compani pharma/biotech industri would detriment growth
prospect busi repres nearli half avtr revenu base well effort
supplier disintermedi vwr channel busi threat new entrant channel
busi would hurt outlook final integr risk associ vwr merger
anoth sourc potenti downsid
downsid risk overweight rate includ limit follow factor first
weaken diagnost end market driven european lab consolid competit
pressur diabet otherwis would detriment compani prospect well
increas competit key product categori digit pcr blood type
diagnost trend could hurt investor sentiment stori futur outlook final
execut risk associ sap implement margin expans plan remain potenti
sourc downsid expect
downsid risk equal weight rate includ limit follow factor first
slowdown demand compani main end market exposur notabl pharma/biotech
compani repres nearli half tech top line exposur major end market
academic/govern clinic market roughli split remain exposur would hurt
worsen academic/govern fund trend well slower uptak key product categori
 simpl western multiplex elisa patholog epi prostat cancer test would hurt growth
outlook final acquisit target select integr risk could lead downsid
upsid risk equal weight rate includ faster expect growth key product
categori simpl western patholog prostat cancer test well continu stronger
expect growth core proteins/antibodi busi
downsid risk overweight rate includ limit follow factor first
due compani intern footprint global macro deterior particular deterior
demand trend china would weigh futur growth prospect well slowdown demand
pharma/biotech compani major end market would neg outlook given
compani exposur structur proteom intensifi competit dynam busi
would hurt expect profit growth final acquisit target select integr risk
also stand potenti headwind go forward
downsid risk overweight rate includ limit follow factor
sustain reduct fund therapeut compani would neg
impact outlook charl river larg pharma merger histor result
least temporari demand disrupt research product servic risk steadi growth
final acquisit target select integr risk also stand potenti headwind go
downsid risk overweight rate includ limit follow factor first
given scale recent deal flow acquisit target select integr risk stand
potenti headwind investor interest stori second signific global exposur lead risk
neg impact global macro deterior gener well china headwind
specif final competit pressur especi diagnost could weigh futur profit
downsid risk equal weight rate includ limit follow factor first
slowdown demand capit equip hospit would limit potenti futur growth
secondli extens cervic cancer screen interv would neg
impact downsid risk includ potenti increas competit molecular diagnost
acquisit target select integr
upsid risk equal weight includ improv demand hospit addit expans
cervic cancer screen interv limit competit molecular diagnost well faster
expect margin improv across busi line could lead increas investor appetit stand
upsid risk rate
downsid risk equal weight rate includ limit follow factor
sustain reduct fund therapeut compani would weight futur growth opportun
pipelin repriorit and/or merger larg pharma specif iclr outsiz
exposur would disrupt potenti growth margin gain addit downsid risk includ continu
soften backlog convers well intensifi competit pressur industri
upsid risk equal weight rate includ greater longer expect margin expans
cycl compani well addit upsid risk includ compani see sale growth
acceler solid increment margin
upsid risk underweight rate includ limit follow factor first
faster larger contribut popul sequenc program weve model would provid
potenti upsid compar estim well market see faster adopt
diagnost greater forecast rebound china faster ramp consum growth
gener could see investor appetit name increas could see downsid risk
continu pattern downward guidanc revis investor becom disillus stori
downsid risk overweight rate includ limit follow factor first
sustain reduct fund therapeut compani could lead neg outlook
name addit pipelin repriorit larg pharma larg pharma merger
histor result least temporari demand disrupt research product
servic sentiment name could hurt final exist risk tech/data synergi
contract research busi fail materi profit expect would limit
downsid risk overweight rate includ limit follow factor first
price pressur diagnost above/beyond alreadi contempl
would see risk neg rel impact margin expect continu pressur
diagnost util share loss hospital-affili lab and/or sustain reduct fund
therapeut compani would see neg risk factor lh well pipelin repriorit
larg pharma larg pharma merger histor result least temporari demand
disrupt research product servic could neg implic profit growth
outlook final acquisit target select integr remain materi part compani
growth strategi potenti risk disrupt avenu could limit attract investor
downsid risk equal weight rate includ limit follow factor first
due compani intern footprint global macro deterior particular deterior
demand trend china would weigh futur growth prospect well slowdown demand
pharma/biotech compani major gener end market would neg outlook
given compani exposur packag food food retail industri pressur
would also add downsid risk rate final moder mtd industry-lead price
power could add margin pressur risk outlook profit growth
upsid risk equal weight includ turnaround acceler demand trend
china gener packag food food retail market larg rel exposur
compar peer addit upsid risk includ strengthen compani price power
outsiz margin accret due
downsid risk equal weight rate includ limit follow factor first
due compani intern footprint global macro deterior particular deterior
demand trend china would weigh futur growth prospect well continu weak
demand food test market would weigh market sentiment addit downsid risk
includ unsuccess new product servic launch well acquisit target select
upsid risk equal weight includ better expect growth outpac guidanc
expect achiev high bar investor set compani growth trajectori well
turnaround acceler demand trend china food test market would view
increment posit investor
downsid risk equal weight rate includ limit follow factor first
downsid potenti continu compani execut challeng especi china
well organiz disrupt compani search perman ceo
anticip taken neg final addit downsid risk includ increas competit
molecular diagnost well acquisit target select integr
upsid risk equal weight rate includ faster expect turnaround resolut
compani execut challeng well compani place new ceo make
posit impress sharehold earli lay new clearli articul achiev
strategi could see market sentiment improv faster expect
upsid risk underweight rate includ limit follow factor first
compani achiev faster share gain weve model could
increment upsid forecast valuat expect secondli greater execut cost
effici program off-set price pressur materi could underestim margin
process result unforeseen price relief potenti industri particip find
downsid risk equal weight rate includ limit follow factor first
given view compani organ end market exposur support acceler growth see
acquisit target select integr risk potenti headwind go forward secondli due
compani intern footprint global macro deterior particular deterior
demand trend china would weigh futur growth prospect well worsen
academic/govern fund trend slowdown demand pharma/biotech compani also
upsid risk equal weight rate includ stronger expect growth compani
gener end market within specif custom mix lead improv growth outlook
well compani execut deliv accret deal investor bullish could
addit upsid compar equal weight rate
upsid risk underweight rate includ limit follow factor first
manag deliv faster anticip rebound wat growth rate could upsid
expect secondli faster uptak new product anticip faster growth
lc/m biolog qc anticip exposur would
improv outlook compani compar forecast risk upsid also includ
intensifi competit dynam structur proteom solid execut acquisit target
select integr
